An interim analysis of non-interventional study of the epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia
B. Ya. Alekseev,
K. M. Nyushko,
R. A. Gafanov,
A. A. Kirichek,
Yu. V. Anzhiganova,
E. I. Kopyltsov,
Yu. Yu. Sundui,
V. B. Matveev https://doi.org/10.17650/1726-9776-2020-16-3-90-101
Abstract
Objective: to study the clinical and demographic profile of patients with non-metatstatic castration-resistant prostate cancer (nmCRPC) and clinical approaches to the treatment of nmCRPC in the context of daily medical practice before and after progression M1 stage.
Materials and methods. The multicenter non-interventional epidemiological study is planned to include 200 patients with a documented diagnosis of nmCRPC from 2019 to 2020. The interim report has included data on 108 patients from 13 centers located in different regions of the Russian Federation. The median age of the patients was 73 (55—90) years.
Results and conclusion. When the diagnosis of nmCRPC was made, the median prostate specific antigen was 8.23 (0.17—116.9) ng/ml, and the prostate specific antigen doubling time was 6 (1—50) months. When diagnosed nmCRPC, 86 patients (79.6 %) underwent a change of therapy, of which 42 % were prescribed modern regimens containing the new generation non-steroid antiandrogens (apalutamide, enzalutamide).
Keywords
non-metastatic castration-resistant prostate cancer,
prostate-specific antigen doubling time,
new generation antiandrogen,
androgen deprivation therapy
Supporting agencies: The study was performed with the support of Johnson & Johnson. Authors express thanks to all patients who agreed to participate in this study, their families, as well as doctors and other medical staff who took care of them, research supervisors, including Prof. B.Ya., Alekseev, Prof. V.B. Matveev, research fellows, including K.M. Nyushko, R.A. Gafanov, A.A. Kirichek, P.S. Borisov, A.K. Nosov, Yu.V. Anzhiganova, D.V. Tevs, A.V. Zyryanov, V.A. Atduev, A.L. Gorbachev, P.A. Karnaukh, E.I. Kopyltsov, M.F. Urmantsev, S.N. Dimitriadi, Yu.Yu. Sundui, S.A. Kalinin.
About the Authors
B. Ya. Alekseev
National Medical Research Radiological Center, Ministry of Health of Russia; Medical Institute of Continuing Education, Moscow State University of Food Production
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284; 11 Volokolamskoe Shosse, Moscow 125080.
Competing Interests:
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284; 11 Volokolamskoe Shosse, Moscow 125080.
Competing Interests:
The authors declare no conflict of interest.
K. M. Nyushko
National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284.
Competing Interests:
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284.
Competing Interests:
The authors declare no conflict of interest.
R. A. Gafanov
Russian Scientific Center of Roentgen Radiology, Ministry of Health of Russia
Russian Federation
86 Profsoyuznaya St., Moscow 117997.
Competing Interests:
Russian Federation
86 Profsoyuznaya St., Moscow 117997.
Competing Interests:
The authors declare no conflict of interest.
A. A. Kirichek
Moscow City Oncological Hospital No. 62, Moscow Healthcare Department
Russian Federation
27 Istra, Moscow region 143423.
Competing Interests:
Russian Federation
27 Istra, Moscow region 143423.
Competing Interests:
The authors declare no conflict of interest.
Yu. V. Anzhiganova
A.I. Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary
Russian Federation
16 1st Smolenskaya St., Krasnoyarsk 660133.
Competing Interests:
Russian Federation
16 1st Smolenskaya St., Krasnoyarsk 660133.
Competing Interests:
The authors declare no conflict of interest.
E. I. Kopyltsov
Clinical Oncology Dispensary
Russian Federation
Build. 1, 9 Zavertyaeva St., Omsk 644013.
Competing Interests:
Russian Federation
Build. 1, 9 Zavertyaeva St., Omsk 644013.
Competing Interests:
The authors declare no conflict of interest.
Yu. Yu. Sundui
City Clinical Cancer Hospital No. 1, Moscow Healthcare Department
Russian Federation
Competing Interests:
Russian Federation
17 / 1 Baumanskaya St., Moscow 105005.
Competing Interests:
The authors declare no conflict of interest.
V. B. Matveev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
24 Kashirskoe Shosse, Moscow 115478.
Competing Interests:
Russian Federation
24 Kashirskoe Shosse, Moscow 115478.
Competing Interests:
The authors declare no conflict of interest.
References
1. Malignant tumors in Russia in 2018 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMITS radiologii” Minzdrava Rossii, 2019. 250 p. (In Russ.).
2. State of oncological care in Russia in 2018. Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMITS radiologii” Minzdrava Rossii, 2019. 236 p. (In Russ.).
3. Clinical guideline by the Russian Association of Oncologists. Prostate cancer. 2019. Available at: https://oncology-association.ru/clinical-guidelines-kr (accessed: 13.12.2019). (In Russ.).
4. Mottet N., Cornford P., van den Bergh R.C.N. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Eur Urol 2018. Available at: https://uroweb.org/guideline/prostate-cancer.
5. Kirby M., Hirst C., Crawford E.D. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65(11):1180-92. DOI: 10.1111/j.1742-1241.2011.02799.x.
6. Li T.T., Shore N.D., Mehra M. et al. Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized disease. Cancer 2017;123(18):3591-601. DOI: 10.1002/cncr.30784.
7. Tombal B. Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient? Ann Oncol 2012;23 Suppl 10:x251-8. DOI: 10.1093/annonc/mds325.
8. Marteau F., Gimonet G., Gabriel S. et al. Epidemiology of patients with metastatic castrate resistant prostate cancer in Europe and Australia. Value Health 2014;17(7):A619. DOI: 10.1016/j.jval.2014.08.2188.
9. Liede A. International prevalence of nonmetastatic (M0) castration-resistant prostate cancer (CRPC). J Clin Oncol 2017;31(15_suppl).
10. Howard L.E., Moreira D.M., De Hoedt A. et al. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int 2017;120(5B): E80-6. DOI: 10.1111/bju.13856.
11. Smith M.R., Cook R., Lee K.A., Nelson J.B. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 2011;117(10):2077-85. DOI: 10.1002/cncr.25762.
12. Smith M.R., Kabbinavar F., Saad F. et al. Natural history of rising serum prostatespecific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005;23(13):2918-25. DOI: 10.1200/JCO.2005.01.529.
13. Scher H.I., Morris M.J., Stadler W.M. et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 2016;34(12):1402-18. DOI: 10.1200/JCO.2015.64.2702.
14. Virgo K., Basch E., Loblaw D.A. et al. Second-line hormonal therapy for men with chemotherapy-naive, castrationresistant prostate cancer: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 2017;35(17):1952-64. DOI: 10.1200/JCO.2017.72.8030.
15. Fendler W.P. Poster presentation at SUO 2018. Annotation No. 202. (In Russ.).
16. Saad F., Chi K.N., Finelli A. et al. The 2015 CUA0CUOG guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J 2015;9(3-4):90-6. DOI: 10.5489/cuaj.2526.
17. American Cancer Society. Cancer Facts & Figures. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf. Accessed May 2020.
18. Smith M.R., Saad F., Chowdhury S. et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018;378(15):1408-18. DOI: 10.1056/NEJMoa1715546.
19. Hussain M., Fizazi K., Saad F. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018;378(26):2465-74. DOI: 10.1056/NEJMoa1800536.
20. Small E., Saad F., Chowdhury S. et al. Final survival results from SPARTAN, a phase 3 study of apalutamide (APA) vs placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO 2020. Poster presentation (Abstract #5516).
21. Recommendations on the treatment of prostate cancer. Available at: http://cr.rosminzdrav.ru/#!/recomend/99. (In Russ.).
Review
For citations:
Alekseev B.Ya., Nyushko K.M., Gafanov R.A., Kirichek A.A., Anzhiganova Yu.V., Kopyltsov E.I., Sundui Yu.Yu., Matveev V.B. An interim analysis of non-interventional study of the epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia. Cancer Urology. 2020;16(3):90-101. (In Russ.) https://doi.org/10.17650/1726-9776-2020-16-3-90-101
Views:
716
Email this article 